Enhancing the quality and scale of the development pipeline
First written in FY2019. 11 of 17 entries say "Restated". Latest entry: 2026-09-11.
The whole theme swung hardest in 2025: 2 of 8 companies on the "Worse" side.
1 other company's latest entry also says "Advanced".
- 2026-09-11AdvancedFinancial results presentation
「For Redasemtide, patient trials have already begun in epidermolysis bullosa, acute ischemic stroke, ischemic cardiomyopathy, chronic liver disease and knee osteoarthritis.」
The company specifically disclosed a pipeline of 5 programs in which patient trials have already begun. - FY2025AdvancedAnnual report
「Through multifaceted screening of candidate substances, supported by continued research and development investment aimed at selecting next-generation development candidates, we have identified new candidate compounds with significant activity, namely TRIM3, TRIM4 and TRIM5.」
TRIM5 has been added to TRIM3 and TRIM4 as an explicitly named new candidate compound, broadening the development pipeline. - FY2024AdvancedAnnual report
「The company recognizes as an essential goal for enhancing corporate value and stabilizing management not only advancing these development programs but also expanding indications further, advancing development of follow-on pipeline products and exploring new development candidates, thereby enhancing its development pipeline in both quality and scale.」
In addition to continuing retasemtiv development, the policy of expanding indications, advancing the follow-on pipeline and exploring new candidates was reconfirmed. For TRIM3 and TRIM4, the report also described the accumulation of experimental data from disease-model animals and progress in out-licensing activities. - FY2024-Q3RestatedAnnual report
「In its project to discover novel regenerative medicine candidate compounds other than retasemtiv, the company has continued active R&D investment to select next-generation development candidates and conducted multifaceted candidate-compound screening, ultimately identifying multiple novel candidate compounds with significant activity.」
The explanation that multiple novel candidate compounds had been identified through R&D investment and multifaceted screening has been reconfirmed. - FY2024-Q1RestatedAnnual report
「In its project to discover novel regenerative medicine candidate compounds other than retasemtiv, the company has continued active R&D investment to select next-generation development candidates and conducted multifaceted candidate-compound screening, ultimately identifying multiple novel candidate compounds with significant activity.」
The explanation that multiple novel candidate compounds had been identified through R&D investment and multifaceted screening has been reconfirmed. - FY2023-Q1RestatedAnnual report
「In its project to discover novel regenerative medicine candidate compounds other than retasemtiv, the company has continued active R&D investment to select next-generation development candidates and conducted multifaceted candidate-compound screening, ultimately identifying multiple novel candidate compounds with significant activity.」
The explanation that multiple novel candidate compounds had been identified through R&D investment and multifaceted screening has been reconfirmed. - FY2022RestatedAnnual report
「For multiple candidate substances identified through our research to date, therapeutic effects have been confirmed in efficacy studies using disease-model animals, and patent applications for some of them have been completed. We are steadily building on these results.」
In light of efficacy confirmation in animal models for multiple candidate compounds and completion of some patent applications, the policy of enhancing the quality and scale of the pipeline has been reconfirmed. - FY2022-Q1RestatedAnnual report
「In its project to discover novel regenerative medicine candidate compounds other than retasemtiv, the company has continued active R&D investment to select next-generation development candidates and conducted multifaceted candidate-compound screening, ultimately identifying multiple novel candidate compounds with significant activity.」
The explanation that multiple novel candidate compounds had been identified through R&D investment and multifaceted screening has been reconfirmed. - FY2021RestatedAnnual report
「For multiple candidate substances identified through our research to date, therapeutic effects have been confirmed in efficacy studies using disease-model animals, and patent applications for some of them have been completed. We are steadily building on these results.」
In light of confirmation of efficacy for multiple candidate compounds and completion of some patent applications, the policy of enhancing the quality and scale of the pipeline has been reconfirmed. - FY2021-Q3RestatedAnnual report
「In its project to discover novel regenerative medicine candidate compounds other than retasemtiv, the company has continued active R&D investment to select next-generation development candidates and conducted multifaceted candidate screening, ultimately identifying multiple novel candidate compounds with significant activity.」
The explanation that multiple novel candidate compounds had been identified through R&D investment and multifaceted screening has been reconfirmed. - FY2021-Q2RestatedAnnual report
「In its project to discover novel regenerative medicine candidate compounds other than retasemtiv, the company has continued active R&D investment to select next-generation development candidates and conducted multifaceted candidate screening, ultimately identifying multiple novel candidate compounds with significant activity.」
The identification of multiple candidate compounds through R&D investment and multifaceted screening has been reconfirmed. - FY2021-Q1RestatedAnnual report
「In its project to discover novel regenerative medicine candidate compounds other than the HMGB1 peptide, the company has continued active R&D investment to select next-generation development candidates and conducted multifaceted candidate screening, ultimately identifying multiple novel candidate compounds with significant activity.」
The explanation that multiple candidate compounds had been identified through R&D investment and multifaceted screening has been reiterated. - FY2020AdvancedAnnual report
「For multiple candidate substances identified through our research to date, therapeutic effects have been confirmed in efficacy studies using disease-model animals, and patent applications for some of them have been completed. We are steadily building on these results.」
Therapeutic effects were confirmed in animal models for multiple new candidates, and patent applications were completed for some of them. - FY2020-Q3RestatedAnnual report
「In its project to discover novel regenerative medicine candidate compounds other than the HMGB1 peptide, the company has continued active R&D investment to select next-generation development candidates and conducted multifaceted candidate screening, ultimately identifying multiple novel candidate compounds with significant activity.」
The explanation that multiple novel candidate compounds had been identified through active R&D investment and multifaceted screening has been reiterated. - FY2020-Q2RestatedAnnual report
「In its project to discover novel regenerative medicine candidate compounds other than the HMGB1 peptide, the company has continued active R&D investment to select next-generation development candidates and conducted multifaceted candidate screening, ultimately identifying multiple novel candidate compounds with significant activity.」
The previous explanation that multiple novel candidate compounds had been identified through R&D investment and multifaceted screening has been reiterated. - FY2020-Q1AdvancedAnnual report
「Through continued investment in research and development aimed at selecting next-generation development candidates and multifaceted screening of candidate substances, we have identified multiple new candidate compounds with significant activity.」
The company explains that multifaceted screening and research and development investment have led to the identification of multiple new candidate compounds, expanding the development pipeline. - FY2019First statedAnnual report
「We recognize that expanding into other indications, advancing development of follow-on pipelines and identifying new development candidates to strengthen our development pipeline in both quality and quantity are essential goals for enhancing corporate value and stabilizing management.」
The company has set a goal of strengthening its pipeline through expansion of indications for lead products, development of follow-on products and identification of new candidates.